MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- TORRENT PHARMACEUTICALS LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Torrent Pharma Quarterly Results 
(TORR)
Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
Torrent Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-16* |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 14,430 | 14,340 | 13,740 | 14,290 | 14,770 | 17,220 | 18,720 | 18,940 | |
| Other income | Rs m | 500 | 1,040 | 1,050 | 780 | 740 | 420 | 270 | 100 | |
| Turnover | Rs m | 14,930 | 15,380 | 14,790 | 15,070 | 15,510 | 17,640 | 18,990 | 19,040 | |
| Expenses | Rs m | 11,270 | 11,390 | 10,770 | 11,000 | 11,180 | 13,580 | 13,950 | 14,210 | |
| Gross profit | Rs m | 3,160 | 2,950 | 2,970 | 3,290 | 3,590 | 3,640 | 4,770 | 4,730 | |
| Depreciation | Rs m | 730 | 970 | 800 | 840 | 940 | 1,510 | 1,500 | 1,520 | |
| Interest | Rs m | 480 | 580 | 560 | 510 | 800 | 1,210 | 1,220 | 1,260 | |
| Profit before tax | Rs m | 2,450 | 2,440 | 2,660 | 2,720 | 2,590 | 1,340 | 2,320 | 2,050 | |
| Tax | Rs m | 160 | 380 | 780 | 680 | 2,010 | -940 | 690 | 260 | |
| Profit after tax | Rs m | 2,290 | 2,060 | 1,880 | 2,040 | 580 | 2,280 | 1,630 | 1,790 | |
| Gross profit margin | % | 21.9 | 20.6 | 21.6 | 23.0 | 24.3 | 21.1 | 25.5 | 25.0 | |
| Effective tax rate | % | 6.5 | 15.6 | 29.3 | 25.0 | 77.6 | -70.1 | 29.7 | 12.7 | |
| Net profit margin | % | 15.9 | 14.4 | 13.7 | 14.3 | 3.9 | 13.2 | 8.7 | 9.5 | |
| Diluted EPS | Rs | 13.5 | 12.2 | 11.1 | 12.1 | 3.4 | 13.5 | 9.6 | 10.6 | |
| Diluted EPS (TTM) | Rs | 64.1 | 55.2 | 49.0 | 48.9 | 38.8 | 40.1 | 38.6 | 37.1 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Torrent Pharma 2QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ALEMBIC PHARMA WYETH LTD PLETHICO PHARMA BIOCON LTD VENUS REMEDIES
Compare TORRENT PHARMA With: ALEMBIC PHARMA WYETH LTD PLETHICO PHARMA BIOCON LTD VENUS REMEDIES
Compare TORRENT PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Trades Marginally Higher; Asian Paints & Axis Bank Top Gainers(12:30 pm)
Share markets in India are presently trading on a positive note. Barring IT sector, all sectoral indices are trading in green with stocks in the realty sector and finance sector.
Views on news
TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)
Dec 11, 2018RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.
Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)
Dec 7, 2018This stock has corrected 30% from peak and looks attractive at these valuations.
Should You Deploy Your Savings In Mirae Asset Equity Savings Fund?(Outside View)
Dec 7, 2018PersonalFN briefly sheds light on the NFO: Mirae Asset Equity Savings Fund and the investment risk associated in it along with its outlook.
Should You Alter Your Mutual Fund Portfolio Based on the Election Results?(Outside View)
Dec 11, 2018PersonalFN explains why mutual fund houses seem to be in two minds now and what should investors do in these times.
More|
| |
TORRENT PHARMA SHARE PRICE
Dec 19, 2018 02:43 PM
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA 5-YR ANALYSIS
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.